BenchSci vs Causaly: Comparing AI Platforms for Drug Discovery

Preclinical research is scattered across thousands of data sources, hundreds of models, and a stack of tools that were never built to work together. A wave of AI platforms now promises to pull that work into one place. For an R&D organization, the real question is which one to trust with the science itself, from the first target hypothesis through the IND package.

EMET by BenchSci and Causaly both come up in that decision. Both are built for life sciences rather than adapted from a general-purpose AI product, both reason over biomedical evidence, and both cite their answers back to a source. Causaly, based in London, is an agentic AI platform that retrieves evidence, reasons over curated knowledge graphs, and automates research workflows across the R&D pipeline. EMET is narrower on purpose, built only for biopharma R&D and its preclinical core.

This piece measures the two platforms on five things a preclinical organization depends on: the depth of each system's biology-specific workflows, the data it can reason over, the service that drives adoption, the freedom to use the best model for each task, and whether the vendor could become a competitor. The two are evenly matched on two of these. On the other three, BenchSci pulls ahead.

What to look for in AI for preclinical R&D

When you evaluate AI for preclinical R&D, the demo rarely tells you what you need to know. The traits that decide whether a platform is still earning its place a year later are structural, and they are easy to skip when the output on screen looks polished. Five of them do most of the work.

• Depth of biology-grounded workflow and integration. Preclinical work is spread across thousands of data sources and hundreds of tools, and it runs from a literature question to a sequencing run to a decision at the bench. Value comes from a platform that acts across that whole span, not one that stops at the evidence summary.
• Proprietary, science-specific evidence to reason over. A model can only reason as well as the evidence beneath it. Curated, structured biology that a competitor cannot reach beats a general index of the same public sources, and the gap is widest on the questions that decide a program.
• A service model that drives adoption. Buying software changes nothing on its own about how a lab works. People on the ground who build workflows for specific teams are what decide whether the tool is still in use a year later.
• The freedom to use the best model for each task. No single model wins every scientific job, and the frontier moves constantly. A platform welded to one lab's models inherits that lab's roadmap, pricing, and outages.
• A partner that will not become a competitor. You are handing this system your targets, your assays, and the programs that define your pipeline. Whether the vendor might one day develop drugs of its own matters before that IP leaves your walls.

Few platforms carry all five with equal weight. A specialist evidence platform can be excellent at retrieval and reasoning while leaving the pipeline execution, the deepest data, and the rollout lighter than a preclinical team needs. The sections below take EMET and Causaly through each criterion in turn.

Criterion 1: Depth of biology-grounded workflow and integration

Discovery does not live inside a chat box. It moves from a literature question to an omics dataset to a decision at the bench, and it is specific to biology at every step. The question is how much of that work the platform can actually do, not just describe.

Causaly is a strong evidence and reasoning layer

Causaly is good at what it is built for. Its agentic research agents plan, search, reason, and conclude across internal and external biomedical data, turning a complex question into an evidence-backed answer in hours rather than weeks. It reads deep biology through its Bio Graph and maps the competitive landscape through its Pipeline Graph, and it now codifies expert methods into repeatable workflows that agents run for any program.

That covers a real span of R&D, from target identification to regulatory evidence. It is decision-support work: finding, synthesizing, and reasoning over evidence to inform a call. Causaly is built to get scientists to a defensible answer, and it does that well.

EMET runs the science, not only the evidence around it

Biology has fragmented across thousands of sources and hundreds of tools, and scientists lose 40% to 60% of their time to finding and cleaning data. Closing that gap means executing the work, not only summarizing what is known about it. EMET carries 200+ proprietary scientific skills and more than 250 agents and workflows that move a program across the full preclinical journey, from target identification and validation through lead optimization, safety, and IND-enabling studies.

It also does the analysis itself. EMET runs bioinformatics pipelines such as FastQC and RNA-seq differential expression from inside the conversation, fetches and visualizes protein structures, and retrieves ADMET data. It connects to your internal and proprietary data through connectors BenchSci's scientists build for each account, and acts in the lab through a lab-in-the-loop design.

Fusing those pieces into one biology-grounded system is what makes EMET a platform rather than a marketplace, where the value comes from binding the pieces together, not from the pieces themselves. Each new connector and workflow raises the value of the next. An evidence layer tells you what the literature supports; EMET takes the next step and does the experiment-adjacent work that follows.

Criterion 2: The data and evidence the platform reasons over

Both platforms reason over a curated biomedical knowledge graph, so the presence of a graph is not the dividing line. The dividing line is what sits inside it: a body of evidence a competitor cannot reach, or an index built from sources most vendors can license too.

Causaly built a high-precision biomedical knowledge graph

Causaly's data work is serious. Its Scientific Knowledge Graph holds 500M facts and 70M directional relationships, paired with a Pipeline Graph that maps the drug pipeline landscape and its data pipelines ingest and extract from more than 100,000 documents a day. A retrieval system ranks for relevance, flags no-answer cases, and returns cited evidence.

It is purpose-built for biomedical reasoning. Much of it is drawn from the published and licensable literature, extended by publisher partnerships that let its agents read full text through a customer's own institutional licenses.

BenchSci reasons over closed-access science and experimental data no one else holds

Evidence sets the ceiling on any answer, and a decade of BenchSci's data work sits under EMET. The platform reasons over a proprietary Biological Evidence Knowledge Graph of 858M nodes and 2.2B relationship edges, one of the largest structured maps of disease and target biology built for drug discovery. Beneath it sit 38M+ publications, 16M of them closed-access papers opened through eight years of licensing with Elsevier, Springer Nature, Wiley, Oxford University Press, and others.

The part that is hardest to match is not the literature. It is the reagent and model-systems layer: 16M antibodies, 22M RNAi entries, 18M CRISPR records, 500K cell lines, and 700K animal models, curated by a team of 60 PhD scientists. That experimental layer answers the practical questions that decide a bench experiment, and it exists in EMET and nowhere else.

A neuro-symbolic evaluation loop ties every generated output back to that verified graph, reaching 95%+ accuracy on biological questions across 600+ tests and 8+ benchmarks, two to four times what frontier models manage alone. Both platforms cite their sources; the difference is the depth and exclusivity of what each one is citing from.

Criterion 3: The service model that drives adoption

Good software still dies if nobody adopts it. Whether a platform survives its first year rarely comes down to the interface. It comes down to who shows up to bend the tool around each team's real work. Both vendors staff that work with scientists, but BenchSci commits the more embedded team.

Causaly staffs deployment with PhD scientists

Causaly does not hand customers a login and walk away. Its professional services bring PhD scientists together with dedicated science and change-management teams, and they cover strategic alignment, deployment planning, adoption, and the codification of a team's specialized workflows. For an enterprise standing up AI across R&D, that support is a real strength and worth weighing.

BenchSci embeds a dedicated scientific team per account

BenchSci structures the same idea more deeply. Every deployment comes with a dedicated team of PhD scientists fluent in your biology and your therapeutic areas, who work alongside your researchers and build to your stack.

That team leads training, steers the change, and builds the connectors and workflows that fit how your people actually operate, tailored per organization rather than pulled off a shelf. It stays involved as an ongoing scientific partner. When the workflows are built around the organization, the platform gets adopted instead of shelved. The two companies agree that science adoption takes scientists; BenchSci commits a standing team to each account to make it stick.

Criterion 4: Model flexibility and vendor independence

No lab holds the frontier for long, so the platforms worth committing to are the ones free to reach for a better model whenever one appears. This is the first of two criteria where BenchSci and Causaly land in the same place.

Causaly selects models under a governed orchestration layer

Causaly is not built on a single foundation model. Its governed orchestration framework selects the tools, models, and data for each agent, cross-validates between them, and applies quality control at each step, and its enterprise data fabric integrates outside data, APIs, and agentic frameworks. A customer's research is not welded to one model vendor's roadmap.

BenchSci is model-agnostic and routes every task to the best model

Because EMET builds no model of its own, every question can go to whatever performs best on it. It selects per step across 40+ models: a frontier model for open reasoning, a specialized biomedical model such as ESM-2 or AbLang2 where sequence or structure is the question, and each new frontier model folded in as it ships.

The mechanism differs between the two. EMET routes automatically to the best model for each scientific task, while Causaly assigns models to agents inside its own orchestration. On the question that decides lock-in, whether your research is tied to one lab's models, both platforms answer the same way.

Criterion 5: Whether your AI partner also develops drugs

In drug discovery the vendor relationship is unusually intimate. You are trusting a partner with your targets, your assays, and the programs that define your pipeline, so it is fair to ask whether that partner might one day develop drugs of its own. This is the second criterion where the two platforms stand on the same ground.

Causaly is a research-intelligence vendor with no drug program

Causaly sells software for finding, visualizing, and interpreting biomedical knowledge. It has no in-house therapeutics business and no drug pipeline of its own, and its work runs through its customers' programs rather than any Causaly asset. On neutrality, a preclinical team has little to worry about here.

BenchSci has committed never to develop its own drugs

BenchSci stays on the tooling side of the line by design and has committed never to discover its own drugs. For a pharma organization handing over its most sensitive IP, that permanent commitment is a clean trust signal, and it is structural rather than a promise: BenchSci's only path to winning is to make your scientists more effective. Neutrality is built into how EMET runs, inside your own cloud, with your data isolated and never used to train a shared model.

So neutrality is not where these two separate. Unlike some frontier labs that have entered drug discovery themselves, both Causaly and BenchSci are tooling vendors that can make the same commitment today. The real separation runs through the other three criteria: the depth of the work each platform does, the data it reasons over, and the people who make it stick.

Which platform belongs in preclinical R&D

This was never an argument about whether Causaly is good. It is a strong, purpose-built evidence and reasoning platform, it reasons over a serious biomedical knowledge graph, and it invests in the services that drive adoption. Across the five criteria that decide a preclinical platform, EMET and Causaly are evenly matched on two, model flexibility and neutrality, and on the other three the separation runs in BenchSci's favor.

EMET runs the science end to end, from a literature question to a bioinformatics pipeline to a lab-in-the-loop experiment, where Causaly informs the decision that precedes that work. EMET reasons over 16M closed-access papers and a PhD-curated reagent database that exist nowhere else, where Causaly indexes largely licensable literature. And BenchSci embeds a dedicated, standing team of PhD scientists in every account.

Causaly is a capable choice for teams whose main need is faster, cited evidence synthesis and competitive intelligence. EMET by BenchSci is built to go further into the science itself: grounded in proprietary biology, executing the analysis, deployed inside your walls, and staffed by scientists. When the question is where your programs and your data will live for the next several years, that is the difference that lasts.

See what EMET does on your own targets. Book a demo with the BenchSci team.